TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7056949
Drug: Rinkel-method immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rinkel-method immunotherapy
Study: 31502662
Drug: Monopolar radiofrequency
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monopolar radiofrequency device with single microneedle, 3 treatments at 4-week intervals
Study: 30076270
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day donepezil (in apolipoprotein ϵ 4 non-carriers)
Study: 20089774
Drug: Lactobacillus salivarius
Normalized name: Lactobacillus Salivarius
DrugBank: Lactobacillus salivarius (DB16544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus salivarius CUL61 and Lactobacillus paracasei CUL08 and Bifidobacterium animalis subsp. lactis CUL34 and Bifidobacterium bifidum CUL20; 1 x 10(10) colony-forming units administered daily during the last month of pregnancy and to infants aged 0-6 months.
Study: 17697906
Drug: ER oxycodone
Normalized name: oxycodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER oxycodone
Study: 12188097
Drug: Naltrexone (NTX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (NTX), 50 mg/day
Study: 10553752
Drug: D-serine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-serine (30 mg/kg per day)
Study: 6851723
Drug: Heparin-dihydergot 2500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-dihydergot 2500 (2 X 2500 IU) with 0.5 mg dihydroergotamine (DHE)
Study: 6851723
Drug: Conventional low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional low dose heparin regimen (2 X 5000 IU)
Study: 26569165
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea beverages with low catechin content (149.5 mg catechins with a galloyl moiety)
Study: 26569165
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea beverages with high catechin content (246.5 mg catechins with a galloyl moiety)
Study: 25012418
Drug: SSRI (escitalopram
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI (escitalopram or citalopram) or dual therapy (serotonergic agent)
Study: 22398243
Drug: MVA-mBN32 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-mBN32 vaccine after first immunization
Study: 22398243
Drug: MVA-mBN32 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-mBN32 vaccine after second immunization
Study: 22398243
Drug: MVA-mBN32 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-mBN32 vaccine
Study: 20104460
Drug: Milrinone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (50 microg/kg bolus followed by 0.5 microg/kg/min infusion for 24 hours)
Study: 16248851
Drug: Phenserine tartrate
Normalized name: chlorpheniramine
DrugBank: Phenserine (DB04892)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenserine tartrate 10 mg
Study: 16248851
Drug: Phenserine tartrate
Normalized name: chlorpheniramine
DrugBank: Phenserine (DB04892)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenserine tartrate 5 mg
Study: 16248851
Drug: Phenserine tartrate
Normalized name: chlorpheniramine
DrugBank: Phenserine (DB04892)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenserine tartrate 20 mg
Study: 12137863
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg daily on days 5‐9 after menses
Study: 12137863
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 50 mg daily on days 5‐9 after menses
Study: 7993190
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) administration of recombinant human erythropoietin (rhEPO) at a median dose of 33 U/kg body weight three times a week
Study: 7993190
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) administration of recombinant human erythropoietin (rhEPO) at a median dose of 22 U/kg body weight
Study: 7993190
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) administration of rhEPO
Study: 7993190
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) administration of rhEPO
Study: 178197
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of glucagon
Study: 6783023
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (1200 mg daily for one week)
Study: 30007519
Drug: Automated VR
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated VR treatment (delivered in roughly six 30‐min sessions over a 2‐week period)
Study: 26518514
Drug: 1250 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1250 mg/day omega‐3 fatty acid + vitamin E placebo
Study: 26518514
Drug: 1250 mg
Normalized name: bran 1250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1250 mg omega‐3 fatty acids/day + 400 IU/day vitamin E
Study: 24999060
Drug: Long-term medication
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term medication assisted treatment (LT-MAT) with buprenorphine/naloxone (BUP/NX)
Study: 24999060
Drug: Short-term medication
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term medication assisted treatment (ST-MAT) with buprenorphine/naloxone (BUP/NX)
Study: 22836073
Drug: Rosuvastatin 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 80 mg once weekly
Study: 20598959
Drug: US-guided pes
Normalized name: Ipomoea pes-caprae flowering top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-guided pes anserinus bursa injections
Study: 20598959
Drug: Unguided pes
Normalized name: Ipomoea pes-caprae flowering top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unguided pes anserinus bursa injections
Study: 12411528
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker (CCB), amlodipine, administered for 7 days prior to and for 7 days following the damage protocol
Study: 12411528
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker (CCB), amlodipine
Study: 7860392
Drug: Interdigitating chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interdigitating chemotherapy and radiotherapy (COPE followed by thoracic radiation therapy)
Study: 7860392
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy and radiotherapy (DDP and etoposide with concurrent thoracic radiation therapy)
Study: 7860392
Drug: Prophylactic cranial
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic cranial irradiation (PCI) after completion of chemotherapy
Study: 31903865
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone treatment in euthyroid women with thyroid autoimmunity
Study: 31903865
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone treatment for TSH >4 mIU/L
Study: 30740877
Drug: Topical phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical phenytoin 2% powder spray
Study: 30049503
Drug: Morphine ARER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine ARER 100 mg
Study: 30049503
Drug: Extended-release morphine
Normalized name: morphine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release morphine 100 mg
Study: 21558456
Drug: Saquinavir-boosted ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir-boosted ritonavir at therapeutic dose (1000/100 mg bid)
Study: 21558456
Drug: Saquinavir-boosted ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir-boosted ritonavir at supratherapeutic dose (1500/100 mg bid)
Study: 21558456
Drug: Positive control
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive control (moxifloxacin 400 mg)
Study: 17531335
Drug: Combined schedule
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined schedule of external beam treatment (35.75 Gy in 13 fractions) followed by high dose rate brachytherapy (17 Gy in two fractions)
Study: 16366808
Drug: Brief Relationship
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Relationship Therapy (BRT)
Study: 16366808
Drug: Standard Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Behavioral Couples Therapy (S-BCT)
Study: 16366808
Drug: Psychoeducational Attention
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Psychoeducational Attention Control Treatment (PACT)
Study: 10418023
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of cefepime (Group 1, n = 9)
Study: 10418023
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion of cefepime (Group 2, n = 9)
Study: 7739307
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin infusion (partial thromboplastin time 1.5‐2 times baseline)
Study: 7739307
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin (adjusted dose with partial thromboplastin time 1.5‐2 times baseline)
Study: 2298592
Drug: 200 or
Normalized name: Mag-200 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 or 400 ml ice water ingestion
Study: 24886235
Drug: STAIR Narrative
Normalized name: fluorexon stain
Approvals — FDA: no, EMA: no, PMDA: no
Description: STAIR Narrative Therapy
Study: 18579575
Drug: Long-term antidepressant
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term antidepressant medication in patients with MDD
Study: 18579575
Drug: Acute administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute administration of citalopram to controls
Study: 9927101
Drug: 5-mg pilocarpine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg pilocarpine tablets (20 mg/d)
Study: 9927101
Drug: 2.5-mg pilocarpine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5-mg pilocarpine tablets
Study: 7752293
Drug: Therapy coupled
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy coupled with urine monitoring
Study: 2196772
Drug: DL‐diltiazem (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL‐diltiazem (0.4 mg/kg as a bolus intravenously, followed by an infusion of 15 mg/hr)
Study: 31529059
Drug: 250 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 μg Synacthen
Study: 29753264
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg dexamethasone
Study: 22101218
Drug: Self-Administered Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-Administered Therapy (SAT)
Study: 23768797
Drug: BodiMojo intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BodiMojo intervention for four weekly health class periods
Study: 15315844
Drug: Modified WHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified WHO regimen (Rifampicin 600 mg once a month supervised, 50 mg of Clofazimine and 100 mg of Dapsone daily unsupervised) and BCG 0.1 mg per dose 6 monthly
Study: 15315844
Drug: Multi-drug treatment
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-drug treatment (MDT) and Mw (2 x 10(8) killed bacilli per dose) 6 monthly
Study: 15315844
Drug: Multi-drug treatment
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-drug treatment (MDT) with 0.1 ml of distilled water 6 monthly (control group)
Study: 15315844
Drug: Both immunotherapy
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both immunotherapy groups (groups I and II)
Study: 15315844
Drug: Immunotherapy groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy groups (groups I and II)
Study: 8040775
Drug: Vancomycin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (25 micrograms/ml)
Study: 2647033
Drug: Cotazym‐S‐Forte (10,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotazym‐S‐Forte (10,000 BP units of lipase activity per capsule)
Study: 2647033
Drug: Pancrease (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancrease (5000 BP units of lipase activity per capsule)
Study: 20668324
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) 2.4 g/day for 2 years
Study: 16614398
Drug: EGG (640
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGG (640 mg/d additional dietary cholesterol and 600 microg lutein + zeaxanthin)
Study: 16614398
Drug: SUB (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUB (0 mg/d cholesterol, 0 microg lutein + zeaxanthin)
Study: 14714357
Drug: Puerarin Injection
Normalized name: PUERARIA MIRIFICA ROOT
DrugBank: Puerarin (DB12290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puerarin Injection (PI) 200 ml by intravenous dripping once a day, starting one week before operation.
Study: 14714357
Drug: Puerarin Injection
Normalized name: PUERARIA MIRIFICA ROOT
DrugBank: Puerarin (DB12290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puerarin Injection (PI)
Study: 10810000
Drug: 6 weeks
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 weeks of oral antivitamin K therapy
Study: 10810000
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of oral antivitamin K therapy
Study: 8908224
Drug: Morphine IW,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine IW, saline IM
Study: 8908224
Drug: Saline IW,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline IW, morphine IM
Study: 1920184
Drug: five-week daily
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: five-week daily exercise training
Study: 1920184
Drug: exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: exercise training including six sessions of relaxation therapy
Study: 27299516
Drug: Systemic-behavioral treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic-behavioral treatment modules of the SELBST program
Study: 23289958
Drug: CoQ10 200
Normalized name: CoQ10 200mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 200 mg d(‐1) for 3 months
Study: 22522761
Drug: Pretransplant donor-specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretransplant donor-specific antibodies
Study: 22522761
Drug: Non-donor-specific antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-donor-specific antibodies
Study: 22522761
Drug: Posttransplant donor-specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posttransplant donor-specific antibodies
Study: 11842916
Drug: 320 mg
Normalized name: aspirin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg Ginkgo biloba/Panax ginseng combination
Study: 11842916
Drug: 640 mg
Normalized name: glycerin 1640 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 640 mg Ginkgo biloba/Panax ginseng combination
Study: 11842916
Drug: 960 mg
Normalized name: glycerin 960 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 960 mg Ginkgo biloba/Panax ginseng combination
Study: 7846134
Drug: Continuous-wave ultrasound
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous-wave ultrasound at a dosage of 1.5 W/cm2 for 5 minutes
Study: 2689046
Drug: Carteolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carteolol (20 mg daily)
Study: 28645475
Drug: Melatonin (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (intravenous and intracoronary bolus)
Study: 16971295
Drug: Supportive Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive Therapy for Adherence to Antiretroviral Treatment (STAART)
Study: 27249080
Drug: Doxazosin XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin XL (4 mg/d to 16 mg/d over 12 days)
Study: 27249080
Drug: Placebo (matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matched capsules)
Study: 24504804
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) 250 mg/day
Study: 24504804
Drug: Meloxicam 7.5
Normalized name: meloxicam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 7.5 mg/day
Study: 12375378
Drug: Daily self-observation
Normalized name: DAILY SELF DISCOVERY SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily self-observation measure of parental disciplinary behavior (diary)
Study: 8672315
Drug: Local anaesthetic
Normalized name: Local anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthetic alone (lignocaine 10 mg ml‐1 - bupivacaine 3.75 mg ml‐1)
Study: 8672315
Drug: Local anaesthetic
Normalized name: Local anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthetic with adrenaline (5 micrograms ml‐1)
Study: 8672315
Drug: Local anaesthetic
Normalized name: Local anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthetic with hyaluronidase (75 iu ml‐1)
Study: 2104079
Drug: Oral tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral tobramycin
Study: 31189519
Drug: IDegLira (insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDegLira (insulin degludec plus liraglutide)
Study: 31189519
Drug: IGlar U100
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGlar U100 (insulin glargine 100 units/mL)
Study: 28332372
Drug: Aceclofenac controlled
Normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aceclofenac controlled release (CR) 200 mg once daily
Study: 19890073
Drug: Selegiline transdermal
Normalized name: Selegiline Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline transdermal system (STS) 3 mg/24 h
Study: 19890073
Drug: Selegiline transdermal
Normalized name: Selegiline Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline transdermal system (STS) 6 mg/24 h
Study: 15542048
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol treatment (1 mg 17-beta-estradiol + 1 mg drosperinone or 2 mg drosperinone or 3 mg drosperinone)
Study: 15542048
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol treatment (45 microg 17-beta-estradiol + 30 microg levonorgestrel or 40 microg levonorgestrel)
Study: 15542048
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and transdermal estradiol therapy
Study: 10235427
Drug: Napsagatran 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Napsagatran 5 mg/h
Study: 10235427
Drug: Napsagatran 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Napsagatran 9 mg/h
Study: 9308743
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (control)
Study: 8315426
Drug: Continuous bladder
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous bladder irrigation with 200 mL/h of normal saline
Study: 8315426
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion mesna at 100% of the cyclophosphamide dose
Study: 27135916
Drug: Probiotic capsules
Normalized name: Quad-Probiotic Capsules
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic capsules (Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, 2 × 10(9) CFU/g each) for 8 weeks
Study: 27135916
Drug: Placebo (cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cellulose capsules) for 8 weeks
Study: 10588564
Drug: Ropivacaine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 7.5 mg/mL, n = 73
Study: 10588564
Drug: Bupivacaine 2.5
Normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2.5 mg/mL, n = 71
Study: 6685512
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate tape (1 piece, 40 mg/tape)
Study: 6685512
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate tape (2-3 pieces, 40 mg/tape)
Study: 31368588
Drug: Drug filling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug filling group (triamcinolone acetonide clotrimazole injected into the external auditory canal)
Study: 31368588
Drug: Drug smearing
Normalized name: Caladryl Clear
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug smearing group (smearing antifungal cream once per day)
Study: 23905372
Drug: Pengyan Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pengyan Pill (PP) - 10 g each time, thrice daily for 14 consecutive days
Study: 23905372
Drug: Azithromycin -
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin - 10 g each day for 7 consecutive days